Hr Her2 News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Hard questions on maui. How did this wildfire start . How did it grow so fast . Destroy lives all with so little warning . Now a top official in charge of the response to that crisis has quit even as he stands up for how his agency handled the disaster. Plus a historic hurricane. Hilary is now a huge category four storm. It could be the first storm of its kind to hit california in some 84 years. Some areas could get a years worth of rain in just one day. And justice deferred. Donald trumps legal team trying to push one trial years into the future. While the former president backtracks his plan...

Pooja Advani, MBBS, MD, discusses the potential utilization of capivasertib plus fulvestrant in hormone receptor–positive, HER2-negative breast cancers with PIK3/AKT/PTEN pathway alterations.

Investigators continue to evaluate HER2 expression as well as CDK4/6 inhibitor use for hormone receptor–positive/HER2-negative breast cancer.

In breast cancer coverage this year, topline results from the phase 3 NATALEE trial made waves in March, with our other most-read content in the space covering an expanded indication for abemaciclib, revised screening recommendations, a new potential treatment to reduce radiation exposure, and the benefits of diet and exercise on patient outcomes.

This phase 3 study investigated sacituzumab govitecan, a Trop-2–directed antibody-drug conjugate, vs treatment of physician’s choice in pretreated patients who have endocrine-resistant hormone receptor–positive/HER2-negative breast cancer, the most common form of breast cancer.